Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells 7,886 Shares of Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Azmi Nabulsi sold 7,886 shares of Phathom Pharmaceuticals stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $51,968.74. Following the completion of the transaction, the chief operating officer now owns 233,390 shares in the company, valued at approximately $1,538,040.10. This represents a 3.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Azmi Nabulsi also recently made the following trade(s):

• On Thursday, December 19th, Azmi Nabulsi sold 1,118 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total value of $8,944.00.

Phathom Pharmaceuticals Trading Down 3.8 %

NASDAQ PHAT opened at $6.90 on Friday. Phathom Pharmaceuticals, Inc. has a fifty-two week low of $6.07 and a fifty-two week high of $19.71. The stock has a 50 day simple moving average of $8.04 and a two-hundred day simple moving average of $12.50.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.57) by $0.25. The business had revenue of $16.35 million during the quarter, compared to analysts’ expectations of $12.54 million. During the same period in the previous year, the business earned ($0.76) EPS. On average, sell-side analysts expect that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on PHAT. Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th.

Institutional Investors Weigh In On Phathom Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Jennison Associates LLC lifted its holdings in Phathom Pharmaceuticals by 20.4% in the fourth quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock worth $57,348,000 after buying an additional 1,196,118 shares during the period. Portolan Capital Management LLC grew its holdings in shares of Phathom Pharmaceuticals by 50.4% during the 3rd quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock worth $30,735,000 after acquiring an additional 569,829 shares during the period. Checkpoint Capital L.P. raised its position in shares of Phathom Pharmaceuticals by 71.9% in the 3rd quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company’s stock worth $27,198,000 after acquiring an additional 629,307 shares in the last quarter. FMR LLC lifted its stake in shares of Phathom Pharmaceuticals by 49,000.7% in the 3rd quarter. FMR LLC now owns 1,304,114 shares of the company’s stock valued at $23,578,000 after purchasing an additional 1,301,458 shares during the period. Finally, State Street Corp boosted its position in shares of Phathom Pharmaceuticals by 17.5% during the third quarter. State Street Corp now owns 922,788 shares of the company’s stock valued at $16,684,000 after purchasing an additional 137,539 shares in the last quarter. Institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.